Premium
Chemotherapeutic treatment of the NB rat adenocarcinoma androgen‐insensitive tumor III
Author(s) -
Drago Joseph R.
Publication year - 1982
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930210415
Subject(s) - cyclophosphamide , medicine , prostatic adenocarcinoma , chemotherapy , adenocarcinoma , prostate , oncology , metastasis , platinum , doxorubicin , urology , cancer research , cancer , chemistry , biochemistry , catalysis
Single and combination chemotherapy were evaluated in the treatment of these Nb rat prostate adenocarcinomas. Single‐agent treatment consisted of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), cyclophosphamide, adriamycin, and cis‐platinum; the combination therapy included BCNU and adriamycin; BCNU, adriamycin, and 5‐fluorouracil; cyclophosphamide and cis‐platinum; adriamycin and cis‐platinum; and adriamycin, cis‐platinum, and cyclophosphamide. Controls had a metastatic incidence of 46%. The best results as measured by tumor volume and low incidence of metastasis were achieved with triple drug therapy utilizing adriamycin, cis‐platinum, and cyclophosphamide; and cis‐platinum and cyclophosphamide. This tumor, Nb Pr A.I. III, has proven to be the most unresponsive tumor in the Noble prostatic adenocarcinoma prostate model. No animal treated with any of the above regimes had complete tumor regression.